Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. [electronic resource]
Producer: 20090605Description: 2450-6 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Anilides -- administration & dosage
- Antineoplastic Agents, Hormonal -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- blood
- Docetaxel
- Estramustine -- administration & dosage
- Goserelin -- administration & dosage
- Humans
- Male
- Middle Aged
- Mitoxantrone -- administration & dosage
- Nitriles -- administration & dosage
- Prednisone -- administration & dosage
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- blood
- Taxoids -- administration & dosage
- Tosyl Compounds -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.